Foundayo Tablets 5.5mg (30) (POM) ▼

Foundayo▼ (orforglipron) film-coated tablets

Pharmacology: Oral small-molecule (non-peptide) GLP-1 receptor agonist.

Licensed indications:

• Weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one weight-related comorbidity

Administration: Oral, once daily at any time, with no food or water restrictions. Swallow whole. Missed dose: take as soon as possible, never more than one tablet a day. No adjustment for age, renal impairment or mild-to-moderate hepatic impairment. Not recommended in severe hepatic impairment or under 18s.

Report adverse reactions via the MHRA Yellow Card scheme.